home / stock / rhhby / rhhby articles

RHHBY Articles, Roche Holding Ltd ADR - From 12/05/23

Stock Information
Company Name: Roche Holding Ltd ADR
Stock Symbol: RHHBY
Market: OTC
Website: roche.com
Menu
RHHBY RHHBY Quote RHHBY Short RHHBY News RHHBY Articles RHHBY Message Board
Get RHHBY Alerts

News, Short Squeeze, Breakout and More Instantly...
Jim Cramer Highlights 'Transformational' Impact Of Weight Loss Drugs Like Ozempic: Focus Now On 'Potential Winners' From The Same Narrative | Benzinga

What Happened: Jim Cramer outlined fresh investment prospects on Monday, revolving around the growing demand for GLP-1 drugs, typically administere...
Roche Joins Bandwagon To Challenge Novo Nordisk, Eli Lilly For Weight Loss Drugs | Benzinga

Roche Holding AG (OTC: RHHBY) has agreed to acquire a privately held obesity company Carmot Therapeutics, seeking to challenge ...

AstraZeneca Strikes Deal With Absci To Leverage AI In Cancer Drug Discovery: Report | Benzinga

AstraZeneca plc (NASDAQ: AZN) has reportedly finalized a partnership deal valued at up to $247 million with Absci Corporation (NASDA...

FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca | Benzinga

The FDA approved Bristol Myers Squibb And Co's (NYSE: BMY) Augtyro (repotrectinib) for the treatment of adult patients with locally a...
Regeneron's Skin Drugs Propel Revenue In Q3, Witnesses Strong Demand For Higher Dose Version Of Flagship Eye Drug | Benzinga

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned Q3 adjusted EPS of $11.59, up 4% Y/Y, beating the $10.77 Street estimate. Revenues in...

Sarepta/Roche's Closely Watched Duchenne Gene Therapy Faces More FDA Scrutiny - Stock Tanks | Benzinga

Sarepta Therapeutics Inc (NASDAQ: SRPT) released topline results from EMBARK (Study SRP-9001-301) Phase 3 study of Elevidys (delandistrogene m...

Are Your Eyes At Grave Risk? FDA Issues Dangerous Warning Over Popular Drops From CVS, Target, Cardinal Health And More | Benzinga

The U.S. Food and Drug Administration has recently issued a stern warning to the public, advising against the purchase and use of multipl...
Roche Buys Pfizer & Roivant Sciences' Televant In ~$7.1B Deal | Benzinga

Roche Holding AG (OTC: RHHBY) inked a deal to acquire Telavant Holdings, Inc. for $7.1 billion. As per the terms, Roche will pa...

Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant | Benzinga

Roche will gain the rights to develop, manufacture and commercialize RVT-3101 in the US and Japan for the treatment of inflammatory bowel disease...

Roche Reports Nine Months Sales Growth Despite Lower Sales From COVID-19 Products | Benzinga

Roche Holdings AG's (OTC: RHHBY) nine months sales increased by 1% (down 6% in CHF) to CHF 44.1 billion, even though the co...
Previous 10 Next 10